Literature DB >> 1430203

Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs.

A Giacca1, S J Fisher, Z Q Shi, R Gupta, H L Lickley, M Vranic.   

Abstract

It is generally believed that glucose production (GP) cannot be adequately suppressed in insulin-treated diabetes because the portal-peripheral insulin gradient is absent. To determine whether suppression of GP in diabetes depends on portal insulin levels, we performed 3-h glucose and specific activity clamps in moderately hyperglycemic (10 mM) depancreatized dogs, using three protocols: (a) 54 pmol.kg-1 bolus + 5.4 pmol.kg-1.min-1 portal insulin infusion (n = 7; peripheral insulin = 170 +/- 51 pM); (b) an equimolar peripheral infusion (n = 7; peripheral insulin = 294 +/- 28 pM, P < 0.001); and (c) a half-dose peripheral infusion (n = 7), which gave comparable (157 +/- 13 pM) insulinemia to that seen in protocol 1. Glucose production, use (GU) and cycling (GC) were measured using HPLC-purified 6-[3H]- and 2-[3H]glucose. Consistent with the higher peripheral insulinemia, peripheral infusion was more effective than equimolar portal infusion in increasing GU. Unexpectedly, it was also more potent in suppressing GP (73 +/- 7 vs. 55 +/- 7% suppression between 120 and 180 min, P < 0.001). At matched peripheral insulinemia (protocols 2 and 3), not only stimulation of GU, but also suppression of GP was the same (55 +/- 7 vs. 63 +/- 4%). In the diabetic dogs at 10 mM glucose, GC was threefold higher than normal but failed to decrease with insulin infusion by either route. Glycerol, alanine, FFA, and glucagon levels decreased proportionally to peripheral insulinemia. However, the decrease in glucagon was not significantly greater in protocol 2 than in 1 or 3. When we combined all protocols, we found a correlation between the decrements in glycerol and FFAs and the decrease in GP (r = 0.6, P < 0.01). In conclusion, when suprabasal insulin levels in the physiological postprandial range are provided to moderately hyperglycemic depancreatized dogs, suppression of GP appears to be more dependent on peripheral than portal insulin concentrations and may be mainly mediated by limitation of the flow of precursors and energy substrates for gluconeogenesis and by the suppressive effect of insulin on glucagon secretion. These results suggest that a portal-peripheral insulin gradient might not be necessary to effectively suppress postprandial GP in insulin-treated diabetics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430203      PMCID: PMC443235          DOI: 10.1172/JCI116051

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

2.  Radiochemical assay of long-chain fatty acids using 63Ni as tracer.

Authors:  R J Ho
Journal:  Anal Biochem       Date:  1970-07       Impact factor: 3.365

3.  Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects.

Authors:  R Prager; P Wallace; J M Olefsky
Journal:  Diabetes       Date:  1987-05       Impact factor: 9.461

4.  Extrapancreatic effect of somatostatin infusion to increase glucose clearance.

Authors:  R N Bergman; M Ader; D T Finegood; G Pacini
Journal:  Am J Physiol       Date:  1984-09

5.  The metabolic response to the euglycemic insulin clamp in type I diabetes and normal humans.

Authors:  S Zuniga-Guajardo; B Zinman
Journal:  Metabolism       Date:  1985-10       Impact factor: 8.694

6.  Effects of selective insulin or glucagon deficiency on glucose turnover.

Authors:  H L Lickley; G G Ross; M Vranic
Journal:  Am J Physiol       Date:  1979-03

7.  Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia.

Authors:  P E Lins; A Wajngot; U Adamson; M Vranic; S Efendić
Journal:  Diabetes       Date:  1983-07       Impact factor: 9.461

8.  Effect of fatty acids on glucose production and utilization in man.

Authors:  E Ferrannini; E J Barrett; S Bevilacqua; R A DeFronzo
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

9.  Mild type II diabetes markedly increases glucose cycling in the postabsorptive state and during glucose infusion irrespective of obesity.

Authors:  S Efendic; S Karlander; M Vranic
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

10.  Biosynthesis of glucagon (IRG3500) in canine gastric mucosa.

Authors:  T W Hatton; C C Yip; M Vranic
Journal:  Diabetes       Date:  1985-01       Impact factor: 9.461

View more
  18 in total

Review 1.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

2.  Peripheral but not hepatic insulin resistance in mice with one disrupted allele of the glucose transporter type 4 (GLUT4) gene.

Authors:  L Rossetti; A E Stenbit; W Chen; M Hu; N Barzilai; E B Katz; M J Charron
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.

Authors:  A Basu; A Alzaid; S Dinneen; A Caumo; C Cobelli; R A Rizza
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

4.  Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs.

Authors:  K Rebrin; G M Steil; S D Mittelman; R N Bergman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia.

Authors:  S D Mittelman; Y Y Fu; K Rebrin; G Steil; R N Bergman
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

6.  Evidence that insulin can directly inhibit hepatic glucose production.

Authors:  P Maheux; Y D Chen; K S Polonsky; G M Reaven
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

7.  The role of hepatic insulin receptors in the regulation of glucose production.

Authors:  Alan D Cherrington
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

8.  Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus.

Authors:  H Shamoon; S Friedman; C Canton; L Zacharowicz; M Hu; L Rossetti
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance.

Authors:  David Vicent; Jacob Ilany; Tatsuya Kondo; Keiko Naruse; Simon J Fisher; Yaz Y Kisanuki; Sven Bursell; Masashi Yanagisawa; George L King; C Ronald Kahn
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

10.  Hepatic glucose production during intraperitoneal and intravenous closed-loop insulin regulation of blood glucose in type 1 (insulin-dependent) diabetic patients.

Authors:  J J Robert; D Chauvet; D Darmaun; H Leblanc
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.